You are here
- Home
- Therapy Areas
- Oncology/Infection
Faslodex Post Marketing Surveillance
- Disease
- breast cancer
- Drug Name
- Faslodex
- Generic Name
- fulvestrant
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- IV
- Start Date
- Feb 6, 2009
- Study Name
- D6997L00018
- Study Id
- D6997L00018
- ClinicalTrials.gov ID
- NCT00860561
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
